SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: January
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -5.88
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.745

05 Dec
2023

0.015

OPEN

$0.74

2.05%

HIGH

$0.75

911,711

LOW

$0.72

TARGET
$0.817 9.6% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 0.2 0.6 xxx
DPS (cps) xxx 1.0 0.9 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx - 50.0% - 10.0% xxx
PE Ratio xxx N/A 127.5 xxx
Dividend Yield xxx N/A 1.2% xxx
Div Pay Ratio(%) xxx 555.6% 150.0% xxx

Dividend yield today if purchased 3 years ago: 1.69%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.31

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 30/03 - ex-div 0.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx0.2
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx3,660.2 M
Book Value Per Share xxxxxxxxxxxxxxx48.0
Net Operating Cash Flow xxxxxxxxxxxxxxx142.7 M
Net Profit Margin xxxxxxxxxxxxxxx0.05 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx0.38 %
Return on Invested Capital xxxxxxxxxxxxxxx0.25 %
Return on Assets xxxxxxxxxxxxxxx0.15 %
Return on Equity xxxxxxxxxxxxxxx0.38 %
Return on Total Capital xxxxxxxxxxxxxxx-9.09 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx98.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx13 M
Long Term Debt xxxxxxxxxxxxxxx214 M
Total Debt xxxxxxxxxxxxxxx227 M
Goodwill - Gross xxxxxxxxxxxxxxx95 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx17 M
Price To Book Value xxxxxxxxxxxxxxx1.32

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx29.4 M
Capex % of Sales xxxxxxxxxxxxxxx0.80 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,436 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx293 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx16 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxx xx xxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Shaw and Partners

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

21/09/2023

3

Neutral

$0.82

10.07%

Sigma Healthcare has stabilised its business over the past year, Macquarie asserts, addressing significant operating issues.

The broker revises earnings forecasts for FY24 and FY25 down -29.0% and up 21.6%, respectively, given the moving forward of the Chemist Warehouse contract acquisition costs to non-recurring items.

Revenue headwinds are expected over the next year, affected by the cycling of covid-related sales and sales associated with the hospital assets, now disposed. Neutral retained. Target is $0.82.

FORECAST
Macquarie forecasts a full year FY24 dividend of 1.00 cents and EPS of 0.50 cents.
Macquarie forecasts a full year FY25 dividend of 1.60 cents and EPS of 3.10 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

SIG STOCK CHART

FNArena News on SIG

1
Rudi’s View: Bear&Bull Market To Continue (?) In 2024

Dec 06 2023 - Rudi's View
2
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
3
FNArena Corporate Results Monitor – 22-09-2023

Sep 22 2023 - Australia
4
Rudi’s View: Which Stocks To Buy?

Jun 28 2023 - Rudi's View
5
Rudi’s View: Keep Your Focus On What Matters

Jun 21 2023 - Rudi's View

Latest Health & Nutrition News

1
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
2
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
3
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
4
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
5
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
6
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
7
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
8
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
9
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
10
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia